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Abstract
Background—Detection of semen biomarkers in vaginal fluid can be used to assess women’s
recent exposure to semen. Quantitative tests for detection of prostate-specific antigen (PSA)
perform well, but are expensive and require specialized equipment. We assessed two rapid
immunochromatographic strip tests for identification of semen in vaginal swabs.
Study Design—We tested 581 vaginal swabs collected from 492 women. Vaginal secretions
were eluted into saline, and PSA was measured using the quantitative IMx (Abbott Laboratories)
assay. Specimens were also tested using the ABAcard p30 test (Abacus Diagnostics) for detection
of PSA and RSID-Semen test (Independent Forensics) for detection of semenogelin (Sg).
Results—Vaginal swab extraction using saline was compatible with direct assessment of vaginal
swab eluates using ABAcard for PSA detection, but not for Sg detection using RSID. The rapid
PSA test detected 91% of specimens containing semen compared to 74% by the rapid Sg test.
Conclusion—Investigators are urged to optimize vaginal swab specimen preparation methods
for performance of RSID or other tests to detect semen components other than PSA. Previously
described methods for PSA testing are not uniformly applicable to other tests.
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1. Introduction
Measurement of objective markers of semen exposure, rather than reliance on self-reported
behavior or mechanical failure of barrier methods, can improve the accuracy of studies
designed to evaluate contraceptive efficacy. Detection of seminal biomarkers in vaginal
secretions provides objective evidence of a woman’s recent exposure to semen. Prostate-
specific antigen (PSA, also known as p30) has been validated as a reliable marker of semen
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exposure in studies of vaginal specimens obtained after vaginal insemination with different
volumes of semen [1,2]. Seminal biomarkers have long been used in forensic detection of
semen in vaginal specimens in sexual assault cases [3,4]. Both PSA, secreted by the prostate
[5], and semenogelin (Sg), the major seminal vesicle secreted protein in human semen [6],
are useful markers for forensic identification of semen [7–11]. In addition, Y-chromosome
DNA contained within sperm cells can be detected by polymerase chain reaction [12,13].
Rapid, immunochromatographic strip tests for PSA and Sg are available commercially.
We recently reported good performance of the rapid ABAcard p30 test (Abacus Diagnostics,
West Hills, CA, USA) compared to a quantitative assay (IMx PSA, Abbott Laboratories,
Abbott Park, IL, USA) for detection of PSA in vaginal swabs [14]. In the present study, we
compared and contrasted ABAcard for detection of PSA and Rapid Stain Identification test
(RSID-Semen, Independent Forensics, Hillside, Illinois, USA) for detection of Sg to identify
semen in vaginal swab specimens that had been specifically processed using previously
described methods for quantitative PSA detection [1,14–16].
2. Materials and methods
2.1. Vaginal swab specimens
Vaginal swab specimens were obtained from women participating in two different research
studies that are described in detail elsewhere [14]. Briefly, 402 vaginal swabs were from 313
women who participated in a study comparing two methods of STI prevention and control
among sex workers in Dhaka, Bangladesh, conducted from February 2005 through
September 2006, and 179 vaginal swabs were from women who participated in a study
comparing two interviewing techniques to obtain reports of sexual behaviors among
sexually active women in Zimbabwe from November 2006 through January 2007. Women
were not recruited based on the timing of recent intercourse. However, most women (82%)
reported vaginal intercourse (with or without a condom) in the previous 48 h. Women were
recruited into the studies only after providing written informed consent according to Good
Clinical Practice Guidelines. The Bangladesh study was approved by the Biomedical
Institutional Review Board (IRB) of the University of North Carolina at Chapel Hill and the
IRB of the International Center for Diarrhoeal Disease Research, Bangladesh. The
Zimbabwe study was approved by IRBs of Family Health International, the University of
North Carolina at Chapel Hill, the University of California at San Francisco, and by the
ethics review committees of the Medical Research Council of Zimbabwe and the Medicines
Control Authority of Zimbabwe.
Vaginal specimens were collected on cotton-tipped swabs (Falcon™ Screw Cap Single
SWUBE™ applicator, Becton Dickinson and Co., Sparks, MD). Immediately after
collection, swabs were air-dried, stored in screw-capped tubes and shipped at ambient
temperatures to the research laboratory at the University of North Carolina at Chapel Hill.
For recovery of vaginal secretions, each swab was placed into 3.0 mL phosphate-buffered
saline, incubated at room temperature for 15 – 30 min, agitated and pressed against the side
of the tube to elute the sample. Vaginal specimens were centrifuged at 250 × g for 10 min,
and the supernatants were removed from cell pellets and stored at −80°C until testing. These
conditions were chosen specifically for PSA detection using a quantitative assay (IMx PSA;
Abbott Laboratories, Abbott Park, IL, USA) to take advantage of previously established
criteria for detecting recent semen exposure based on PSA concentrations, using these
vaginal swab extraction methods [1,15–17]. Vaginal swab eluates were stored frozen for
variable periods of time (up to 2 years) before testing, however all tests reported here were
performed within a 6-week period. Thus, comparisons between rates of semen detection
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using different testing methods are valid, however, we cannot rule out that semen
components may have degraded during frozen storage.
2.2. Quantitative prostate-specific antigen (PSA) testing
Supernatants (0.20 mL) from vaginal swab eluates were tested using the IMx PSA assay
(Abbott Laboratories, Abbott Park, IL, USA). The enzyme immunoassay measures PSA
concentrations from 0.04 to 50 ng/mL; samples with initial test results >50 ng/mL were
diluted 1:100 with buffered saline and retested to obtain PSA concentrations. Vaginal swab
eluates containing ≤1.0 ng PSA/mL were considered negative; those containing >1.0 ng
PSA/mL were considered positive for detection of semen, as previously described [1].
2.3. Rapid PSA testing
The vaginal swab extraction procedure described above using buffered saline was consistent
with the manufacturer’s instructions for testing using ABAcard (Abacus Diagnostics, West
Hills, CA, USA). We loaded 0.20 mL of vaginal swab eluate directly into the sample well of
the immuno-chromatographic strip test cassette according to the instructions. After a 10-min
incubation at room temperature to allow sample migration throughout the test strip, a
positive result was indicated by pink lines in both test and control areas. A negative result
was indicated by a line in the control area only. A control line was visible in all tests with
vaginal swab eluates, documenting valid ABAcard results. Buffered saline alone produced a
visible line in the control area only. Buffered saline containing 1 ng purified human PSA/mL
produced a faint, but consistently visible line in the test area and lines from solutions
containing ≥5 ng PSA/mL were markedly darker. For this analysis, specimens that produced
any visible line in the test area plus a line in the control area of the strip were considered
positive by the rapid PSA test. A negative rapid PSA result was indicated by a line in the
control area only.
Like all immunoassays that depend on antigen-antibody interactions, the ABAcard test and
the RSID test (described below) are subject to potential interference in the presence of
excess antigen, which impairs immune complex formation. As a result of this so-called
‘high-dose hook effect’, high concentrations of the analyte can give false-negative results.
The threshold concentrations at which rapid semen test results may be subject to the high-
dose hook effect have not been established by the manufacturers. However, our unpublished
observations suggest that this threshold may be between 2,000 and 5,000 ng PSA/mL for the
ABAcard.
2.4. Rapid semenogelin testing
It is important to note that the vaginal swab extraction procedure described above using
buffered saline does not conform with the manufacturer’s instructions for testing with the
Rapid Stain Identification test (RSID-Semen, Independent Forensics, Hillside, Illinois,
USA), which specifies the use of RSID – Semen Extraction Buffer. Nevertheless, we wished
to determine whether the test could be used for detection of Sg in these specimens, as
extraction with buffered saline is commonly used for PSA testing from vaginal swabs. In
initial experiments, buffered saline alone or buffered saline diluted 1:5 in RSID Semen
Running Buffer according to the manufacturer’s instructions was applied to the sample well
of the rapid test strip as directed. Samples that produced a visible line in test and control
areas of the strip were considered positive by the rapid Sg test; those with a line in the
control area only were considered negative. Buffered saline alone produced uniform false-
positive results with visible lines in control and test areas of the strip, whereas buffered
saline diluted 1:5 in running buffer was negative. Accordingly, the vaginal specimens, which
had already been extracted in buffered saline, were diluted 1:5 in running buffer for RSID
testing. A control line was visible in all tests with diluted vaginal swab eluates.
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2.5. Calculations and statistical analyses
As a result of the requirement for specimen dilution and the loading characteristics of the
RSID test device, the amount of vaginal swab eluate tested by RSID was 10-fold lower (5-
fold dilution and half the volume loaded into the sample well) than the corresponding
specimen tested using the ABAcard. To account for the additional dilution of specimens
required for RSID testing, PSA concentrations in specimens were adjusted to one-tenth the
values determined by the quantitative assay in the undiluted vaginal swab eluates for
analysis of RSID results.
The kappa statistic for multiple raters was calculated using the MAGREE macro from SAS/
STAT Software (Release 6.11 TS020). Among four independent evaluators, inter-reader
reliability was substantial for both rapid tests with a kappa score of 0.97 (SE, 0.02) for
ABAcard with a subset of 402 vaginal swab specimens and 0.78 (SE, 0.03) for RSID with a
subset of 207 specimens.
Ninety-five percent confidence intervals (95% CI) for proportions were calculated according
to Wilson[18]. Differences between proportions were assessed by the z-test using Sigma Stat
for Windows version 3.5 (Systat Software, Inc.); p values < 0.05 were considered
statistically significant.
3. Results
Using the quantitative IMx assay for PSA detection, 194/581 (33.4%) vaginal swab
specimens extracted in buffered saline contained >1 ng PSA/mL (Table 1). Both rapid tests
identified positives among specimens containing <1 ng PSA/mL; Sg detection by RSID was
higher among specimens with <1 ng PSA/mL than PSA detection by ABAcard. Among
specimens with >1.0 ng PSA/mL, PSA detection by ABAcard was significantly higher than
Sg detection by RSID. For vaginal swab specimens with >1.0 ng PSA/mL, we also
compared the proportion of rapid test positives among those with low, moderate and high
semen exposure categories as previously defined [15,16] (Table 2). Both ABAcard and
RSID detected semen in all specimens containing high levels of PSA. All low and moderate
PSA-positives were also positive by ABAcard, whereas RSID detected Sg in significantly
fewer specimens with low PSA concentrations.
Because detection of either Sg or PSA is consistent with the presence of semen, we
conducted a secondary analysis in which any vaginal swab specimen containing Sg detected
by a positive RSID test, or >1.0 ng PSA/mL detected by the quantitative assay was
considered to be positive for semen. ABAcard detected 92% of all positives (194/212)
compared to 74% detected by RSID (113/152, p <0.001, z-ratio for proportions).
4. Discussion
We compared qualitative detection of two different semen biomarkers, PSA and Sg, in
vaginal swab specimens extracted in buffered saline using commercially available rapid
immuno-chromatographic strip tests. In addition, PSA concentrations in these specimens
were determined using a quantitative enzyme immunoassay. Using these very same vaginal
swab specimens, we recently reported that the ABAcard rapid test is 100% sensitive (95%
CI, 98–100%) and 96% specific (95% CI, 93–97%) compared to the quantitative test in
detecting >1.0 ng PSA/mL vaginal swab eluate[14]. Although the quantitative IMx PSA
assay may be considered the ‘gold standard’ for detection of PSA, it is not a valid
comparator for the RSID test, which detects Sg, a biochemically distinct analyte. Without a
reference test for detection of Sg, and with acknowledged deviations from the
manufacturer’s directions for specimen processing, we did not attempt to define
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performance characteristics of the RSID test for Sg. Rather, we elected to describe the
percentage of specimens with positive ABAcard or RSID test results and stratify those
observations based on PSA concentrations in the specimens.
In this comparison of two rapid immunochromatographic strip tests for detection of semen
in vaginal swab specimens, PSA was detected by ABAcard significantly more frequently
than Sg was detected by RSID. However, the study has important limitations that must be
considered in interpreting these results. Specimen preparation was compatible with direct
assessment of vaginal swab eluates using ABAcard for PSA detection, but for Sg detection
using RSID, acceptable test performance required 5-fold dilution of samples with running
buffer supplied with the test. The imperfect specimen preparation for use with RSID likely
reduced the sensitivity of the test. To compensate for specimen dilution and lower test
volume (necessitated by a smaller sample well in the RSID test device compared to the
ABAcard), we adjusted PSA concentrations to one-tenth the actual values determined by the
quantitative assay for analysis of RSID test results. However, this adjustment could not
compensate for impaired RSID sensitivity that may have resulted from the use of a different
extraction buffer. Thus, the apparent greater sensitivity of the rapid PSA test compared to
the Sg test for detection of semen in vaginal swabs must be considered to be preliminary and
specific for the specimen preparation methods used in our study. However, these methods
are used commonly, and our experience may benefit others considering the use of RSID for
detection of semen in vaginal fluid.
This study was further complicated by comparing different individual semen components as
markers of this complex biological specimen. Although both Sg and PSA are invariably
present in human semen, individual semen specimens with a detectable level of one
component may not necessarily contain a similarly detectable concentration of the other. Sg
is a natural substrate for cleavage by the serine protease PSA [6], and the concentration of
Sg is inversely correlated with PSA concentration in seminal plasma, independent of the
level of PSA protease activity [19]. Sg cleavage products are detectable by monoclonal
antibodies against Sg [10,19], and the capture antibody in the RSID test does detect cleaved
Sg (K. Reich, Independent Forensics, personal communication). Thus, Sg that had been
cleaved by PSA in a specimen would still theoretically be detectable by RSID, and
specimens in this study with high PSA concentrations were positive with RSID. Sg
concentrations (4 – 68 mg Sg/mL) [20] are generally higher than PSA concentrations (0.2 –
5.5 mg PSA/mL) in seminal fluid [3,21]. Therefore, specimens containing semen in which
Sg but not PSA can be detected are to be expected. Indeed, such specimens were identified
in our study and accounted for approximately 10% of all positive vaginal swab samples in
which either Sg or >1.0 ng PSA/mL was detected. However, PSA was detected in the
absence of Sg in 25% of positive vaginal swab specimens. Suboptimal specimen preparation
for the RSID test, as discussed above, may account for the failure to detect Sg in these
samples. We did not dilute vaginal swab eluates beyond 1:5 with the running buffer supplied
with the test kits for fear of compromising RSID sensitivity even further, however it is
possible that specimens with high concentrations of Sg could have produced false-negative
results. According to the RSID product insert, 20-fold dilution of samples containing large
amounts (3–50 μL) of pure semen eliminates false-negatives resulting from the high-dose
hook effect. We estimate that the dilution of semen in secretions in the vagina and further
into the buffered saline used for extraction of material from vaginal swabs resulted in a 500-
to 5000-fold dilution of semen in samples tested by RSID. Thus, it is unlikely that the high-
dose hook effect affected the RSID results. However, we cannot rule out that some false-
negative results may have occurred if specimens contained unusually high concentrations of
Sg.
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There are several advantages to using PSA as a marker of semen exposure. The use of PSA
allows investigators to capitalize on previous work characterizing the kinetics of PSA
clearance from vaginal swab specimens prepared in the same way that was used in our
study. We do not know the kinetics of Sg clearance or degradation in the vagina or whether
the presence of PSA and Sg in vaginal fluid from women with recent semen exposure are
correlated. Studies are needed to provide the necessary context for interpreting Sg detection
in vaginal swab specimens: How long after semen exposure can Sg be detected in vaginal
fluid? How soon does Sg disappear compared to PSA? What concentrations of Sg
correspond to semen exposure resulting from problems with condom use? We urge
investigators to optimize vaginal swab specimen preparation methods for the performance of
RSID or other semen detection tests and not rely on previously described methods for PSA
testing. Research needs include comparison of specimens collected in buffered saline and
RSID or other buffers for detection of the two semen markers. For rapid PSA detection,
ABAcard is an appropriate, simple and relatively inexpensive test to identify a biological
marker of recent semen exposure in vaginal swabs [14].
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